Published on 20/05/2020

Keywords : Processionary caterpillars

In springtime, in the forest or garden, you might have come across a line of caterpillars following each other in single file. These "processionary" caterpillars are insects with stinging hairs. They can cause inflammatory reactions in humans or animals that can sometimes be serious. ANSES provides you with a few simple protective measures below.

Published on 19/05/2020

Keywords : Plant protection productsPlant protection products, Glyphosate, Active substances

Glyphosate is an active substance used in herbicides and approved by the European Union until December 2022. France is involved in its re-assessment, which will enable a decision to be taken on its re-approval. In 2018, France initiated a national glyphosate withdrawal plan designed to phase out its main uses by late 2020. ANSES is therefore conducting a series of studies on this active substance and the products containing it. Here is an overview of ANSES's missions.

Published on 18/05/2020

Keywords : Toxic plants

Some toxic plants resemble edible plants and may be confused with them, not only in the wild but also in the garden or vegetable patch. Picking plants for consumption is not without risk: 250 cases of confusion are documented every year. ANSES and the network of poison control centres are drawing attention to the risks of mistaking toxic plants for edible ones. The Agency is calling for greater vigilance and has issued advice on avoiding the risk of poisoning.

Published on 22/04/2020

Regulatory reminder In accordance with the provisions of Article R.5141-2 of the Public Health Code, pursuant to sub-paragraph 6 of Article L.5141-16, clinical trials of veterinary drugs constitute one of the stages in the experimentation of veterinary medicinal products.

Updated on 27/04/2020

Keywords : COVID-19, Coronavirus

Since the beginning of the pandemic, ANSES has been making its expertise available to public decision-makers for the prevention of COVID-19-related health risks. The Agency has also been offering its expertise in its specific areas of competence – food and nutrition, animal health, occupational health, etc. – to provide the public with useful guidelines on how to organise daily life and protect health during this period. This page lists all the work carried out by the Agency and provides an overview of its organisation at this unprecedented time.

Updated on 22/04/2020

ANSES-ANMV can issue certificates at the request of pharmaceutical establishments exporting veterinary medicines to third countries (Public Health Code, Article R.5141-127) or medicated feeding stuffs to other European Union Member States or to third countries (Public Health Code, Article R.5141-128).

Updated on 22/04/2020

In accordance with the provisions of Article R. 5141-81 of the Public Health Code, ANSES-ANMV carries out official batch releases of immunological products (OCABR) for rabies vaccines. Batches of inactivated or live rabies vaccines for veterinary use placed on the market in France are subject to an official batch release by the ANMV, which is the competent national authority. This official batch release includes an analysis of the documents relating to the batch manufacture and analytical controls carried out at ANSES's Nancy Laboratory.

Published on 08/04/2020

A stock shortage is defined as a situation in which it is impossible for a beneficiary to obtain supplies of a veterinary medicinal product on the national market. A stock shortage is assessed as critical when it is likely to induce a risk to human health, animal health and welfare.

Published on 08/04/2020

Each year, within its laboratory, the ANMV's Market Surveillance Unit verifies a series of veterinary medicinal products marketed in France.

Published on 08/04/2020

The veterinary medicinal product manufacturer ensures the quality of each batch before placing it on the market. However, there may be occasions when the manufacturer only becomes aware of an incident that occurred during manufacture or distribution after the medicinal product has been marketed. If the medicinal product does not comply with its marketing authorisation, this is known as a quality defect.